0001193125-17-093663.txt : 20170421 0001193125-17-093663.hdr.sgml : 20170421 20170323160803 ACCESSION NUMBER: 0001193125-17-093663 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 CORRESP 1 filename1.htm Acceleration Request

March 23, 2017

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Mail Stop 4546

Washington, D.C. 20549

Attn: Suzanne Hayes

 

Re: Cara Therapeutics, Inc.

Registration Statement on Form S-3

File No. 333-216657

Acceleration Request

  Requested Date: Friday, March 24, 2017
  Requested Time: 4:00 P.M. Eastern Daylight Time

Dear Ms. Hayes:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-216657) (the “Registration Statement”) to become effective on March 24, 2017, at 4:00 p.m. Eastern Daylight Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Darren DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or in his absence, Alison Haggerty at (212) 479-6596.

 

Very truly yours,

Cara Therapeutics, Inc.

By:

   /s/ Josef Schoell
 

 

  Josef Schoell
  Chief Financial Officer

 

cc: Derek Chalmers, Ph.D., D.Sc., Cara Therapeutics, Inc.

Darren K. DeStefano, Cooley LLP

Alison A. Haggerty, Cooley LLP